Breast Carcinoma Cells BT-20 Transfection Kit

Description

Breast cancer is the most prevalent type of cancer in women worldwide. Although breast cancer has been well studied, preclinical breast cancer research remains important for the development of new therapies. The BT-20 cell line was established in 1958 by isolating and culturing cells from primary human breast cancer tumors and has proven to be a successful host for various transfection studies. The cells came from a 74-year-old Caucasian woman with breast cancer. Because the cell line lacks estrogen receptors and does not exhibit amplification of HER2, this makes the BT-20 cell line a powerful research tool for novel gene therapies. In order to facilitate in-depth research, a specific and efficient cell transfection system is essential. To this end, CD BioSciences has developed a specific transfection kit for the BT-20 cell line.